Scholarlink

Purpose <p>Diabetes mellitus (DM) is a&#xa0;negative prognostic factor in patients with brain metastases (BM). It is unknown whether a&#xa0;direct impact of serum glucose levels on survival exists. We aimed to detect a&#xa0;potential association of serum glucose levels before and during radiotherapy with survival in patients with BM.</p> Methods <p>Patients were included in this retrospective exploratory analysis if at least three fasting and non-fasting serum glucose test results before or during treatment were available. Survival was analyzed with uni- and multivariate Cox regression concerning an association with fasting and maximum glucose levels and regarding potentially confounding dexamethasone intake.</p> Results <p>A&#xa0;total of 62&#xa0;patients with BM (15&#xa0;with and 47&#xa0;without DM) were included. Patients with a&#xa0;mean fasting glucose of more than 7.8 mmol/l (upper quartile) showed significantly shorter survival compared to patients of the lower three quartiles (hazard ratio [HR] = 2.05, <i>p</i> = 0.021). Further, maximum blood glucose levels of &gt; 12.0 mmol/l (upper quartile) were associated with shorter survival (HR = 1.95, <i>p</i> = 0.035). In the subset of patients without DM, a&#xa0;trend toward worse survival in patients with higher fasting glucose levels was observed (HR = 2.54, <i>p</i> = 0.099). The negative association of high maximum glucose levels with survival persisted in multivariate analysis independently of steroid administration.</p> Conclusion <p>Strong elevations of fasting and maximum serum glucose levels were associated with a&#xa0;worse prognosis in patients with BM with and without DM. This observation warrants further analysis in larger cohorts and has potential implications for clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hyperglycemia is associated with poor survival in patients with brain metastases treated with radiotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月16日

查看全文
  • Soniya Poudyal,
  • Friederike Rothe,
  • Seong Jeong,
  • Nils Gleim,
  • Peter Hambsch,
  • Franziska Nägler,
  • Kirsten Papsdorf,
  • Thomas Kuhnt,
  • Alonso Barrantes-Freer,
  • Erdem Güresir,
  • Sabine Klagges,
  • Nils Henrik Nicolay,
  • Clemens Seidel

摘要

Purpose

Diabetes mellitus (DM) is a negative prognostic factor in patients with brain metastases (BM). It is unknown whether a direct impact of serum glucose levels on survival exists. We aimed to detect a potential association of serum glucose levels before and during radiotherapy with survival in patients with BM.

Methods

Patients were included in this retrospective exploratory analysis if at least three fasting and non-fasting serum glucose test results before or during treatment were available. Survival was analyzed with uni- and multivariate Cox regression concerning an association with fasting and maximum glucose levels and regarding potentially confounding dexamethasone intake.

Results

A total of 62 patients with BM (15 with and 47 without DM) were included. Patients with a mean fasting glucose of more than 7.8 mmol/l (upper quartile) showed significantly shorter survival compared to patients of the lower three quartiles (hazard ratio [HR] = 2.05, p = 0.021). Further, maximum blood glucose levels of > 12.0 mmol/l (upper quartile) were associated with shorter survival (HR = 1.95, p = 0.035). In the subset of patients without DM, a trend toward worse survival in patients with higher fasting glucose levels was observed (HR = 2.54, p = 0.099). The negative association of high maximum glucose levels with survival persisted in multivariate analysis independently of steroid administration.

Conclusion

Strong elevations of fasting and maximum serum glucose levels were associated with a worse prognosis in patients with BM with and without DM. This observation warrants further analysis in larger cohorts and has potential implications for clinical practice.